🇺🇸 FDA

Company profile · Sponsor

LEXICON

LEXICON PHARMACEUTICALS, INC.

LXRX · NYSE pharma THE WOODLANDS, TX, USA
Pipeline
24
Drugs
1
Patents
8

Quick answer

LEXICON (LXRX) is a pharma company. headquartered in THE WOODLANDS, TX, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker LXRX
Exchange NYSE
Company type pharma
Headquarters THE WOODLANDS, TX, USA
SEC CIK 0001062822

Pipeline (24)

Search pipeline →

  1. PLACEBO SOTAGLIFLOZIN, SOTAGLIFLOZIN

    LEXICON

    Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy

    phase 3 small molecule active

    1 trial

  2. Placebo

    LEXICON

    Type 1 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  3. Placebo

    LEXICON

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  4. Sotagliflozin

    LEXICON

    Obstructive Cardiomyopathy, Hypertrophic

    phase 3 small molecule active

    1 trial

  5. Sotagliflozin

    LEXICON

    Diabetic Nephropathies

    phase 3 small molecule active

    1 trial

  6. Sotagliflozin

    LEXICON

    Type 1 Diabetes Mellitus

    phase 3 small molecule completed

    3 trials

  7. Sotagliflozin

    LEXICON

    Type 2 Diabetes Mellitus

    phase 3 small molecule terminated

    3 trials

  8. Sotagliflozin

    LEXICON

    Heart Failure

    phase 3 small molecule terminated

    2 trials

  9. Sotagliflozin

    LEXICON

    Type 1 Diabetes Mellitus (T1DM)

    phase 3 small molecule completed

    1 trial

  10. Sotagliflozin (SAR439954)

    LEXICON

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    4 trials

  11. Sotagliflozin Low Dose

    LEXICON

    Type 1 Diabetes (T1D)

    phase 3 small molecule active

    1 trial

  12. Telotristat etiprate

    LEXICON

    Carcinoid Syndrome

    phase 3 small molecule completed

    5 trials

  13. 250 mg LX1033 tablets

    LEXICON

    Irritable Bowel Syndrome

    phase 2 small molecule completed

    1 trial

  14. 75 mg LX4211

    LEXICON

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  15. Gemcitabine

    LEXICON

    Locally Advanced Unresectable Pancreatic Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  16. LX1031 High Dose

    LEXICON

    Irritable Bowel Syndrome

    phase 2 small molecule completed

    1 trial

  17. LX3305 low dose

    LEXICON

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  18. LX4211 Low Dose

    LEXICON

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  19. LX6171 High Dose

    LEXICON

    Age-Related Memory Disorders

    phase 2 small molecule completed

    1 trial

  20. LX7101 (0.125%)

    LEXICON

    Primary Open-angle Glaucoma

    phase 2 small molecule completed

    1 trial

  21. LX9211

    LEXICON

    Diabetic Peripheral Neuropathy

    phase 2 small molecule completed

    1 trial

  22. Placebo

    LEXICON

    Postherpetic Neuralgia

    phase 2 small molecule completed

    1 trial

  23. Placebo (blinded)

    LEXICON

    Diabetic Peripheral Neuropathic Pain

    phase 2 small molecule completed

    1 trial

  24. Sotagliflozin

    LEXICON

    Type 1 Diabetes

    phase 2 small molecule active

    2 trials

Drugs (1)

Search drugs →

  1. sotagliflozin

    ZYNQUISTA

    ORAL approved

    A10

Patents (8)

Search patents →

  1. US 12344596

    Solid forms of (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and salts thereof

    Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11730723

    Compounds and methods for treating viral infections

    Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11666575

    Pyrazolo[1,5]pyrimidine-based compounds and methods of their use to treat viral infections

    Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11059907

    Antibodies that bind Notum Pectinacetylesterase

    Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10106569

    Inhibitors of sodium glucose transporter 1 for constipation

    Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9862724

    Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use

    Expires Mon Jan 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9688710

    Inhibitors of sodium glucose cotransporter 1

    Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9682982

    Inhibitors of adapter associated kinase 1, compositions comprising them, and methods of their use

    Expires Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is LEXICON?

LEXICON (LXRX) is a pharma company. headquartered in THE WOODLANDS, TX, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does LEXICON sponsor?

We track 24 ClinicalTrials.gov-linked programs for LEXICON, including PLACEBO SOTAGLIFLOZIN, SOTAGLIFLOZIN and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does LEXICON company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.